FAKTOR-OPTIONSSCHEIN - ZEALAND PHARMA Stock

DE000MG1VGQ4

Real-time Bid/Ask 05:56:40 2024-06-07 EDT
7.09 ^EUR / 7.19 ^EUR	+2.59%

Current month	-10.08%
1 month	-21.71%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ZEALAND PHARMA A/S

Chart FAKTOR-OPTIONSSCHEIN - ZEALAND PHARMA

Latest news about ZEALAND PHARMA A/S

Zealand Pharma A/S : announces that Boehringer Ingelheim's survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis	04:44am	PU
Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis	04:39am	GL
Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL	06-06	GL
Zealand Pharma A/S Announces Boehringer Ingelheim Will Present Positive Results from Phase 2 Trial with Survivalodutide in MASH at EASL	06-06	CI

More news

Quotes 5-day view

Date	Price	Change
24-06-07	7.16	+2.87%
24-06-06	6.96	-19.54%
24-06-05	8.65	+10.19%
24-06-04	7.85	+5.37%
24-06-03	7.45	-3.75%

Delayed Quote Börse Stuttgart

Last update June 07, 2024 at 05:24 am

More quotes

Static data

Product type	Produits Exotiques
Buy / Sell	CALL
Underlying	ZEALAND PHARMA A/S
Issuer	Morgan Stanley
WKN	MG1VGQ
ISIN	DE000MG1VGQ4
Date issued	2024-04-08
Strike	868 kr
Maturity	Unlimited
Parity	4.05 : 1
Emission price	10 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	13.14 €
Lowest since issue	6.96 €
Spread	0.1 €
Spread %	1.33%

Company Profile

Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.

Sector

More about the company

Ratings for Zealand Pharma A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Zealand Pharma A/S

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

651 DKK

Average target price

785.6 DKK

Spread / Average Target

+20.67%

Consensus